Sympathetic Storming After Severe Brain Injury: What to Actually Treat It With
A young ironworker's brain injury has stopped bleeding, but his heart rate and temperature keep spiking every time anyone touches him. The question is which drug quiets the storm without also quieting the exam.
D.W., a 24-year-old ironworker, fell three stories from scaffolding on his second week at a new job site, sustaining diffuse axonal injury without a surgical lesion — the kind of brain injury that doesn't show a single bleed to evacuate, only widespread shear that declares itself over days rather than in one dramatic scan. By day six, his intracranial pressure monitor is out and the acute herniation risk has passed, but a new pattern has taken its place: five or six times a day, usually right after suctioning or turning, his heart rate surges into the 150s, his systolic pressure climbs past 190, he sweats through his gown, and his arms posture, all resolving within twenty minutes without any identifiable new event on repeat imaging. The team scored him using the PSH-Assessment Measure — a Clinical Feature Scale of 17 alongside a Diagnosis Likelihood Tool score of 7, totalling 24 of a possible 29, well past the 17 the instrument sets as its threshold for probable paroxysmal sympathetic hyperactivity — a distinct diagnosis from raised ICP, and one this same brain injury can produce entirely on its own once the diffuse axonal shear disconnects the hypothalamus from the brainstem structures that normally restrain it.
The pharmacology question is not whether to treat — recurrent catecholamine surges of this magnitude carry real hypermetabolic and cardiac cost over a multi-week ICU course — but which agent controls the storm without blunting the one exam that still matters, his ability to localize and track between episodes. Propranolol, lipophilic enough to cross into the central nervous system, blunts the peripheral catecholamine surge directly; a 2012 retrospective study by Patel and colleagues linked beta-blocker exposure in TBI patients to reduced mortality, a signal consistent with dampening the hypermetabolic cost of repeated storming rather than treating any single episode. Clonidine acts centrally to reduce sympathetic outflow at its source, which is mechanistically closer to the actual disconnection driving PSH — but it sedates, and sedation is exactly what a team trying to catch his exam recovering cannot afford to trade away for episode control.
Naming the storm before treating it
Twenty-four of twenty-nine, with episodes this frequent, is not a mild case, and uncontrolled PSH is one of the most reliable things I see delay a patient's transition into active rehabilitation — the hypermetabolic cost alone sets back the whole recovery timeline. I'd start clonidine. It acts where the actual disconnection is happening, centrally, not just on the periphery.
You're right that his episode burden is severe enough to justify treating aggressively — I'm not arguing for undertreatment. But he's six days out from a diffuse injury we still don't have a ceiling on, and clonidine's sedation would blunt exactly the exam I need to trust between episodes. Propranolol gets us real catecholamine control, and Patel's data links it to a mortality benefit in this population, without costing us the ability to see him.
Add gabapentin to propranolol rather than treating this as an either-or between propranolol and clonidine. Gabapentin's evidence base is thinner — small case series, not a randomized trial — but it reduces episode frequency without sedating, which means it can run alongside an exam-preserving beta-blocker instead of forcing the sedation tradeoff clonidine requires. If episodes stay this frequent despite both, clonidine becomes the honest next step, not the first one.
Propranolol titrated to heart rate control, with gabapentin added the same day, cut episode frequency from five or six daily to one or two within seventy-two hours, and his exam continued to improve between episodes — tracking became consistent by day nine.
Left genuinely open: whether clonidine would have controlled the storming faster had it been started first, a question the physiatrist still raises at each rehab-planning check-in, though the team agrees the current regimen's exam-sparing property was worth the slower initial response given how early in his course this decision was made.